首站-论文投稿智能助手
典型文献
Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters
文献摘要:
During the two-year pandemic of coronavirus disease 2019(COVID-19),its causative agent,severe acute respi-ratory syndrome coronavirus 2(SARS-CoV-2),has been evolving.SARS-CoV-2 Delta,a variant of concern,has become the dominant circulating strain worldwide within just a few months.Here,we performed a compre-hensive analysis of a new B.1.617.2 Delta strain(Delta630)compared with the early WIV04 strain(WIV04)in vitro and in vivo,in terms of replication,infectivity,pathogenicity,and transmission in hamsters.When inoculated intranasally,Delta630 led to more pronounced weight loss and more severe disease in hamsters.Moreover,40%mortality occurred about one week after infection with 104 PFU of Delta630,whereas no deaths occurred even after infection with 105 PFU of WIV04 or other strains belonging to the Delta variant.Moreover,Delta630 outgrew over WIV04 in the competitive aerosol transmission experiment.Taken together,the Delta630 strain showed increased replication ability,pathogenicity,and transmissibility over WIV04 in hamsters.To our knowledge,this is the first SARS-CoV-2 strain that causes death in a hamster model,which could be an asset for the efficacy evaluation of vaccines and antivirals against infections of SARS-CoV-2 Delta strains.The underlying molecular mechanisms of increased virulence and transmission await further analysis.
文献关键词:
作者姓名:
Xinghai Zhang;Shaohong Chen;Zengguo Cao;Yanfeng Yao;Junping Yu;Junhui Zhou;Ge Gao;Ping He;Zhuo Dong;Jie Zhong;Jing Luo;Hongping Wei;Huajun Zhang
作者机构:
State Key Laboratory of Virology,Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;University of Chinese Academy of Sciences,Beijing 101409,China;Hubei International Travel Healthcare Center(Wuhan Customs Port Outpatient Department),Wuhan,430040,China
文献出处:
引用格式:
[1]Xinghai Zhang;Shaohong Chen;Zengguo Cao;Yanfeng Yao;Junping Yu;Junhui Zhou;Ge Gao;Ping He;Zhuo Dong;Jie Zhong;Jing Luo;Hongping Wei;Huajun Zhang-.Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters)[J].中国病毒学,2022(06):796-803
A类:
Delta630,WIV04,outgrew
B类:
Increased,pathogenicity,aerosol,transmission,one,SARS,CoV,variant,wild,type,hamsters,During,two,year,pandemic,coronavirus,disease,its,causative,agent,severe,acute,respi,ratory,syndrome,has,been,evolving,concern,become,dominant,circulating,worldwide,within,just,few,months,Here,performed,compre,hensive,analysis,new,compared,early,vitro,vivo,terms,replication,infectivity,When,inoculated,intranasally,more,pronounced,weight,loss,Moreover,mortality,occurred,about,week,after,PFU,whereas,deaths,even,other,strains,belonging,competitive,experiment,Taken,together,showed,increased,ability,transmissibility,To,our,knowledge,this,first,that,causes,model,which,could,asset,efficacy,evaluation,vaccines,antivirals,against,infections,underlying,molecular,mechanisms,virulence,await,further
AB值:
0.51626
相似文献
Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID?19 in a Han Chinese population from Central China
Yi Wu;Xian‑Hui Wang;Xi‑Hua Li;Li‑Yuan Song;Shi‑Long Yu;Zhi‑Cheng Fang;Yu‑Quan Liu;Le‑Yong Yuan;Chun‑Yan Peng;Shen‑Yi Zhang;Wang Cheng;Hong‑Chao Ma;Li‑Feng Wang;Jun‑Ming Tang;Yun‑Fu Wang;Fu‑Yun Ji-Department of Medical Biology,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Biomedical Research,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Human Respiratory Disease,Xinqiao Hospital,The Army Medical University(Third Military Medical University),400037 Chongqing,China;Department of Emergency Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Geriatric Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Immunology,School of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Laboratory Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Hubei Key Laboratory of Embryonic Stem Cell Research,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Neurology,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
Yong-Qiang Deng;Na-Na Zhang;Yi-Fei Zhang;Xia Zhong;Sue Xu;Hong-Ying Qiu;Tie-Cheng Wang;Hui Zhao;Chao Zhou;Shu-Long Zu;Qi Chen;Tian-Shu Cao;Qing Ye;Hang Chi;Xiang-Hui Duan;Dan-Dan Lin;Xiao-Jing Zhang;Liang-Zhi Xie;Yu-Wei Gao;Bo Ying;Cheng-Feng Qin-State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,AMMS,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Key laboratory of Jilin Province for Zoonosis Prevention and Control,Changchun,Jilin,China;Beijing Protein and Antibody R&D Engineering Center,Sinocelltech Ltd,Beijing,China
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Na-Na Zhang;Rong-Rong Zhang;Yi-Fei Zhang;Kai Ji;Xiao-Chuan Xiong;Qian-Shan Qin;Peng Gao;Xi-Shan Lu;Hang-Yu Zhou;Hai-Feng Song;Bo Ying;Cheng-Feng Qin-Department of Virology,State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd.,Suzhou,Jiangsu,China;School of Life Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,China;Institute of Systems Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins
Youwei Xu;Canrong Wu;Xiaodan Cao;Chunyin Gu;Heng Liu;Mengting Jiang;Xiaoxi Wang;Qingning Yuan;Kai Wu;Jia Liu;Deyi Wang;Xianqing He;Xueping Wang;Su-Jun Deng;H.Eric Xu;Wanchao Yin-The CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;Shanghai Jemincare Pharmaceuticals Co.,Ltd.,Shanghai,China;School of Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing,Jiangsu,China;The Shanghai Advanced Electron Microscope Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;University of Chinese Academy of Sciences,Beijing,China;School of Life Science and Technology,ShanghaiTech University,Shanghai,China;Zhongshan Institute for Drug Discovery,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Guangdong,China
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma;Xinghai Zhang;Peiyi Zheng;Peter H.Dube;Weihong Zeng;Shaohong Chen;Qingyu Cheng;Yunru Yang;Yan Wu;Junhui Zhou;Xiaowen Hu;Yan Xiang;Huajun Zhang;Sandra Chiu;Tengchuan Jin-Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;Laboratory of Structural Immunology,CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at Microscale,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA;University of Chinese Academy of Sciences,Beijing,China;Institute of Health and Medicine,Hefei Comprehensive National Science Center,Hefei,Anhui,China
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
Yingdan Wang;Wuqiang Zhan;Jiangyan Liu;Yanqun Wang;Xiang Zhang;Meng Zhang;Lin Han;Yunping Ma;Lu Lu;Yumei Wen;Zhenguo Chen;Jincun Zhao;Fan Wu;Lei Sun;Jinghe Huang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)and Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Fifth People's Hospital,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences,School of Basic Medical Sciences,Fudan University,Shanghai,China;Shanghai Immune Therapy Institute,Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital,Shanghai,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China
Omicron-specific mRNA vaccine elicits potent immune responses in mice,hamsters,and nonhuman primates
Yi Wu;Yanqiong Shen;Namei Wu;Xinghai Zhang;Shaohong Chen;Chang Yang;Junhui Zhou;Yan Wu;Da Chen;Li Wang;Chao Wang;Huajun Zhang;Ninuo Xia;Sandra Chiu;Yucai Wang-Department of Radiology,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;School of Basic Medical Sciences,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;University of Chinese Academy of Sciences,Beijing,China;MOE Key Laboratory for Cellular Dynamics,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;RNAIfa Biotech,Hefei,Anhui,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。